CONMED Corporation (CNMD), a manufacturer of surgical devices, says its payments to doctors are now under federal scrutiny. In December of 2023, the company says it voluntarily informed the U.S. Department of Justice (DOJ) of:

“...potential issues with certain royalty payments related to design surgeons.”

CONMED says the DOJ is now reviewing the matter.

Later in the company’s most recent filing, CONMED inserted new language warning investors of alleged misconduct at the company.

The company also included new language detailing anti-bribery laws like the Foreign Corrupt Practices Act (FCPA) with which it must comply and the Physician Payments Sunshine Act which:

“...requires us to annually report certain payments and other transfers of value we make to U.S.-licensed physicians or U.S. teaching hospitals. Any failure to comply with these laws and regulations could subject us or our officers and employees to criminal and civil financial penalties.”